Literature DB >> 35044808

Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion.

Dario R Roque1,2, Daniela Matei1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35044808      PMCID： PMC8937007          DOI： 10.1200/JCO.21.02667

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

1.  Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.

Authors:  R E Slayton; J A Blessing; P J DiSaia; W A Christopherson
Journal:  Cancer Treat Rep       Date:  1987-06

2.  Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.

Authors:  Christine Rojas; Chunqiao Tian; Matthew A Powell; John K Chan; Nicholas W Bateman; Thomas P Conrads; Rodney P Rocconi; Nathaniel L Jones; Craig D Shriver; Chad A Hamilton; G Larry Maxwell; Yovanni Casablanca; Kathleen M Darcy
Journal:  Gynecol Oncol       Date:  2020-02-04       Impact factor: 5.482

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Authors:  Matthew A Powell; Virginia L Filiaci; Peter G Rose; Robert S Mannel; Parviz Hanjani; Koen Degeest; Brigitte E Miller; Nobuyuki Susumu; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

5.  Integrated Molecular Characterization of Uterine Carcinosarcoma.

Authors:  Andrew D Cherniack; Hui Shen; Vonn Walter; Chip Stewart; Bradley A Murray; Reanne Bowlby; Xin Hu; Shiyun Ling; Robert A Soslow; Russell R Broaddus; Rosemary E Zuna; Gordon Robertson; Peter W Laird; Raju Kucherlapati; Gordon B Mills; John N Weinstein; Jiashan Zhang; Rehan Akbani; Douglas A Levine
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

6.  A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.

Authors:  G Sutton; V L Brunetto; L Kilgore; J T Soper; R McGehee; G Olt; S S Lentz; J Sorosky; J G Hsiu
Journal:  Gynecol Oncol       Date:  2000-11       Impact factor: 5.482

Review 7.  Uterine carcinosarcoma: A review of the literature.

Authors:  Leigh A Cantrell; Stephanie V Blank; Linda R Duska
Journal:  Gynecol Oncol       Date:  2015-03-21       Impact factor: 5.482

Review 8.  Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.

Authors:  W G McCluggage
Journal:  Int J Gynecol Cancer       Date:  2002 Nov-Dec       Impact factor: 3.437

9.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Authors:  Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko K Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim S ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544

10.  Trends of uterine carcinosarcoma in the United States.

Authors:  Koji Matsuo; Malcolm S Ross; Hiroko Machida; Erin A Blake; Lynda D Roman
Journal:  J Gynecol Oncol       Date:  2018-01-05       Impact factor: 4.401
View more
  1 in total

1.  Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation.

Authors:  Tahireh Markert; David L Kolin; Panagiotis A Konstantinopoulos
Journal:  Gynecol Oncol Rep       Date:  2022-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.